Targeted therapy for oesophageal cancer: An overview

Cancer and Metastasis Reviews

Volumn 27, Issue 2, 2008, Pages 273-288

  Syrigos, K N ^a,b   Zalonis, A ^a,b   Kotteas, E ^a,b   Saif, Muhammad Wasif ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biological therapies; Epidermal growth factor (EGFR); Monoclonal antibodies; Vascular endothelial growth factor (VEGF)

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CARBOPLATIN; CELECOXIB; CETUXIMAB; CI 1053; CISPLATIN; CYCLOPHOSPHAMIDE; DEPSIPEPTIDE; DOCETAXEL; DOXORUBICIN; EMB 72000; ERLOTINIB; FLAVOPIRIDOL; FLUOROURACIL; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; MARIMASTAT; MATUZUMAB; NS 938; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PLACEBO; PRINOMASTAT; ROMIDEPSIN; SORAFENIB; SUNITINIB; TRASTUZUMAB; VANDETANIB;

ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; BLEEDING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE REGULATION; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG MECHANISM; DRUG POTENTIATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL TOXICITY; PANCREAS CANCER; PRIORITY JOURNAL; RASH; RECURRENT DISEASE; REVIEW; SQUAMOUS CELL CARCINOMA; THROMBOEMBOLISM; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; ESOPHAGEAL NEOPLASMS; HUMANS;

EID: 43049093315     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10555-008-9117-z     Document Type: Review

References (144)

1. Ajani, J. A., van Cutsem, E., Moiseyenko, V., Tjulandin, S., Fodor, M., Majlis, A., et al. (2003). Docetaxel, cisplatin, 5-fluorouracil compare to cisplatin and 5-fluorouracil for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastic carcinoma: Interim results of a randomized phase III trial (V325). Proceedings of the American Society of Clinical Oncology, 22, 229-237.
2. Blot, W. J., & McLaughlin, J. K. (1999). The changing epidemiology of oesophageal cancer. Seminars in Oncology, 26, 2-8.
3. Enzinger, P. C., & Mayer, R. J. (2003). Esophageal cancer. New England Journal of Medicine, 349, 2241-2252.
4. Mendelsohn, J., & Baselga, J. (2000). The EGF receptor family as targets for cancer therapy. Oncogene, 19, 6550-6565.
5. Lemmon, M. A., & Schlessinger, J. (1994). Regulation of signal transduction and signal diversity by receptor oligomerization. Trends in Biochemical Sciences, 19, 459-463.
6. Schlessinger, J. (2000). Cell signalling by receptor tyrosine kinases. Cell, 103, 211-225.
7. Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. Nature Reviews. Molecular Cell Biology, 2, 127-137.
8. Iihara, K., Shiozaki, H., Tahara, H., Kobayashi, K., Inoue, M., Tamura, S., et al. (1993). Prognostic significance of transforming growth factor-alpha in human esophageal carcinoma. Implication for the autocrine proliferation. Cancer, 71, 2902-2909.
9. Ozawa, S., Ueda, M., Ando, N., et al. (1987). High incidence of EGF receptor hyperproduction in esophageal squamous-cell carcinomas. International Journal of Cancer, 39, 333-337.
10. Ozawa, S., Ueda, M., Ando, N., Shimizu, N., & Abe, O. (1989). Prognostic significance of epidermal growth factor receptor in esophageal squamous cell carcinomas. Cancer, 63, 2169-2173.
11. Shimada, Y., Imamura, M., Watanabe, G., Ushida, S., Harada, H., Makino, T., et al. (1999). Prognostic factors of esophageal squamous cell carcinoma from the perspective of molecular biology. British Journal of Cancer, 80, 1281-1288.
12. Kitagawa, Y., Ueda, M., Ando, N., Ozawa, S., Shimizu, N., & Kitajima, M. (1996). Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clinical Cancer Research, 2, 909-914.
13. Itakura, Y., Sasano, H., Shiga, C., Furukawa, Y., Shiga, K., Mori, S., et al. (1994). Epidermal growth factor receptor overexpression in esophageal carcinoma. An immunohistochemical study correlated with clinicopathologic findings and DNA amplification. Cancer, 74, 795-804.
14. Sudo, T., Mimori, K., Nagahara, H., et al. (2007). Identification of EGFR mutations in esophageal cancer. European Journal of Surgical Oncology, 33, 44-48.
15. Guo, M., Liu, S., & Lu, F. (2006). Gefitinib-sensitizing mutations in esophageal carcinoma. New England Journal of Medicine, 354, 2193-2194.
16. Hickey, K., Grehan, D., Reid, I. M., O' Briain, S., Walsh, T. N., & Hennessy, T. P. (1994). Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer, 74, 1693-1698.
17. Kawaguchi, Y., Kono, K., Mimura, K., Sugai, H., Akaike, H., & Fugii, H. (2007). Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. International Journal of Cancer, 120, 781-787.
18. Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., et al. (2004). Cetuximab monotherapy and cetuximab plus irinotecan-refractory metastatic colorectal cancer. New England Journal of Medicine, 351, 337-345.
19. Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004). Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. Journal of Clinical Oncology, 22, 1201-1208.
20. Bonner, J. A. (2004). Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. Journal of Clinical Oncology, 22, 5507.
21. Vermorken, J. B., Trigo, J., Hitt, R., Koralewski, P., Diaz-Rubio, E., Rolland, F., et al. (2007). Open-label, uncontrolled, multicentre phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. Journal of Clinical Oncology, 25, 2171-2177.
22. Chung, K. Y., Shia, J., Kemeny, N. E., Shah, M., Schwartz, G. K., Tse, A., et al. (2005). Cetuximab shows activity in colorectal cancer patients with tumours that do not express the epidermal growth factor receptor by immunohistochemistry. Journal of Clinical Oncology, 23, 1803-1810.
23. Cohenuram, M., & Saif, M. W. (2007). Panitumumab the first fully human monoclonal antibody: From the bench to the clinic. Anticancer Drugs, 18, 7-15.
24. Khazaeli MB, Lobuglio AF, Falcey JW, et al. (2000). Low immunogenicity of a chimeric monoclonal antibody (MAb), IMC-C225, used to treat epidermal growth factor receptor-positive tumors. Proceedings of the American Society of Clinical Oncology, 16, Abstr 808.
25. Vanhoefer, U., Tewes, M., Rojo, F., Dirsch, O., Schleucher, N., Rosen, O., et al. (2004). Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. Journal of Clinical Oncology, 22, 175-184.
26. Hecht JR, Patnaik A, Malik I, et al. (2004). ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis. Proceedings of the American Society of Clinical Oncology, 22, Abstr 3511.
27. Ciardiello, F., & Tortora, G. (2002). Anti-epidermal growth factor receptors in cancer therapy. Expert Opinion on Investigational Drugs, 11, 755-768.
28. Perez-Soler, R. (2004). Phase II clinical trial data with the epidermal growth factor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clinical Lung Cancer, 6, 20-23.
29. Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., et al. (2007). Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 25, 1960-1966.
30. Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J. Y., et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. Journal of Clinical Oncology, 21, 2237-2246.
31. Taira, N., Doihara, H., Oota, T., Hara, F., Shien, T., Takahashi, H., et al. (2006). Gefitinib, an epidermal growth factor receptor blockade agent, shows additional or synergistic effects on the radiosensitivity of esophageal cancer cells in vitro. Acta Medica Okayama, 60, 25-34.
32. Russo, S. M., Seay, L. L., Raisch, K. P., et al. (2004). EGFR-specific tyrosine kinase inhibitor, Erlotinib, sensitizes esophageal carcinoma cells to ionizing radiation. Presented at: Radiation Research Society Meeting. St Louis.
33. Russo, S. M., Raisch, K. P., Seay, L. L., et al. (2003). Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, as a radiosensitizer for patients with respectable esophageal cancer. Presented at: International Conference on Molecular Targets and Cancer Therapeutics. Boston.
34. Raisch, K. P., Russo, S. M., Seay, L. L., et al. (2003). EGFR-specific tyrosine kinase inhibitor, erlotinib, in combination with ionizing radiation for the treatment of esophageal carcinoma cells. Presented at: International Conference on Molecular Targets and Cancer Therapeutics. Boston.
35. Hara, F., Aoe, M., Doihara, H., Taira, N., Shien, T., Takahashi, H., et al. (2005). Antitumor effect of gefitinib ('Iresa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo. Cancer Letters, 226, 37-47.
36. Hirata, A., Ogawa, S., Kometani, T., Kuwano, T., Naito, S., Kuwano, M., et al. (2002). ZD1839 (Iressa) induces antioangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Research, 62, 2554-2560.
37. Ferry, D. R., Anderson, M., Beddows, K., et al. (2004). Phase II trial of gefitinib (ZD1839) in advanced adenocarcinoma of the esophagus incorporating biopsy before and after gefitinib. Proceedings of the American Society of Clinical Oncology, 23, 317, Abstr 4021.
38. van Groeningen, C., Richel, D., Giaccone, G., et al. (2004). Gefitinib phase II study in second-line treatment of advanced esophageal cancer. Proceedings of the American Society of Clinical Oncology, 23, Abstr 4022.
39. Adelstein, D. J., Rybicki, L. A., Carrol, M. A., Rice, T. W., & Mekhail, T. (2005). Phase II trial gefitinib for recurrent or metastatic esophageal or gastroesophageal junction (GEJ) cancer. Proceedings of the American Society of Clinical Oncology, 23, Abstr 4054.
40. Tew, W. P., Shah, M., Swhartz, G., Kelsen, D., & Ilson, D. H. (2005) Phase II trial of erlotinib for second-line treatment of advanced esophageal cancer. Program and Abstracts of the American Society of Clinical Oncology 2005 Gastrointestinal Cancers Symposium, 85, Abstr 5.
41. Dragovich, T., Mccoy, S., Urba, S. G., Zanner, K. S., Fenoglio-Preiser, C. M., Blanke, C. D., et al. (2005). SWOG 0127 phase II trial of erlotinib in GEJ and gastric adenocarcinomas. Program and Abstracts of the American Society of Clinical Oncology 2005 Gastrointestinal Cancers Symposium, 107, Abstr 49.
42. Dobelbower, M. C., Russo, S. M., Raisch, K. P., Seay, L. L., Clemons, L. K., Suter, S., et al. (2006). Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: A phase I study. Anticancer Drugs, 17, 95-102.
43. Janmaat, M. L., Gallegos-Ruiz, M. I., Rodriguez, J. A., Meijer, G. A., Vervenne, W. L., Richel, D. J., et al. (2006). Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. Journal of Clinical Oncology, 24, 1612-1619.
44. Personeni, N. (2006). Epidermal growth factor receptor gene copy number in esophageal cancer and outcome prediction to gefitinib: Does intratumoral heterogeneity matter? Journal of Clinical Oncology, 24, 5465.
45. Personeni, N. (2007). Outcome prediction to erlotinib in gastroesophageal adenocarcinomas: Can we improve epidermal growth factor receptor and phosphor-AKT testing? Journal of Clinical Oncology, 25, 910.
46. Teraishi, F., Kagawa, S., Watanabe, T., Tango, Y., Kawashima, T., Umeoka, T., et al. (2005). ZD1839 (Gefitinib, 'Iresa'), an epidermal growth factor receptor-tyrosine inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma. FEBS Letters, 579, 4069-4075.
47. Guo, M., Liu, S., Herman, J. G., & Lu, F. (2006). Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450. Cancer Biology and Therapy, 5, 152-155.
48. Guo, M., Liu, S., & Lu, F. (2006). Gefitinib-sensitizing mutations in esophageal carcinoma. New England Journal of Medicine, 354, 2193-2194.
49. Sudo, T., Mimori, K., Nagahara, H., Utsunomiya, T., Fujita, H., Tanaka, Y., et al. (2007). Identification of EGFR mutations in esophageal cancer. European Journal of Surgical Oncology, 33, 44-48.
50. Kwak, E. L., Jankowski, J., Thayer, S. P., Lauwers, G. Y., Brannigan, B. W., Harris, P. L., et al. (2006). Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clinical Cancer Research, 12, 4283-4287.
51. Xia, W., Mullin, R. J., Keith, B. R., Liu, L. H., Ma, H., Rusnak, D. W., et al. (2002). Antitumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene, 21, 6255-6263.
52. Rusnak, D. W., Lackey, K., Affleck, K., Wood, E. R., Alligood, K. J., Rhodes, N., et al. (2001). The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW572016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Molecular Cancer Therapeutics, 1, 85-94.
53. Ako, E., Yamashita, Y., Ohira, M., Yamazaki, M., Hori, T., Kubo, N., et al. (2007). The pan-erB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo. Oncology Reports, 17, 887-893.
54. De Potter, C. R. (1994). The neu oncogene: More than a prognostic indicator? Human Pathology, 25, 1264-1268.
55. Olayioye, M. A., Neve, R. M., Lane, H. A., & Hynes, N. E. (2000). The ErbB signalling network receptor heterodimerization in development and cancer. EMBO Journal, 19, 3159-3167.
56. Graus-Porta, D., Beerli, R. R., Daly, J. M., & Hynes, N. E. (1997). ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalling. EMBO Journal, 16, 1647-1655.
57. Kelsen, D., Ilson, D., Lipton, R., Baylor, L., & Minsky, B. (1999) A phase I trial of radiation therapy (RT) plus concurrent fixed dose cisplatin (C) with escalating doses of paclitaxel (P) as a 96 hour continuous infusion in patients (pts) with localized esophageal cancer (EC). Proceedings of the American Society of Clinical Oncology, 18, Abstr 1039.
58. Ross, J. S., & McKenna, B. J. (2001). The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Investigation, 19, 554-568.
59. De Castro, J., Gonzalez Baron, C. P., Gamallo, C., Ordonez, A., Espinosa E., et al. (1997). Predictive value of p53, E-Cadherin and erbB-2 in patients with squamous cell esophageal carcinoma. Proceedings of the Annual Meeting-American Society of Clinical Oncology, 16, Abstr 1018.
60. Lam, K. Y., Tin, L., & Ma, L. (1998). C-erbB-2 protein expression in esophageal squamous epithelium from esophageal squamous cell carcinomas, with special reference to histological grade of carcinoma and pre-invasive lesions. European Journal of Surgical Oncology, 24, 431-435.
61. Mimura, K., Kono, K., Hanawa, M., Mitsui, F., Sugai, H., Miyagawa, N., et al. (2005). Frequencies of HER-2/neu expression and gene amplification in patients with esophageal squamous cell carcinoma. British Journal of Cancer, 92, 1253-1260.
62. Nakamura, T., Nekarda, H., Hoelscher, A. H., Bollschweiler, E., Harbeck, N., Becker, K., et al. (1994). Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus. Cancer, 73, 1785-1794.
63. Brien, T. P., Odze, R. D., Sheehan, C. E., McKenna, B. J., & Ross, J. S. (2000). HER-2/neu gene amplification by Fish predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Human Pathology, 31, 35-39.
64. Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., et al. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Journal of Clinical Oncology, 17, 2639-2648.
65. Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Jr, Davidson, N. E., et al. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New England Journal of Medicine, 353, 1673-1684.
66. Kono, K., Takahashi, A., Ichihara, F., Sugai, H., Fujii, H., & Matsumoto, Y. (2002). Impaired antibody-dependent cellular cytotoxicity mediated by Herceptin in patients with gastric cancer. Cancer Research, 62, 5813-5817.
67. Mimura, K., Kono, K., Hanawa, M., Kanzaki, M., Nakao, A., Ooi, A., et al. (2005). Trastuzumab-mediated antibody-dependent cellular cytotoxicity against esophageal squamous cell carcinoma. Clinical Cancer Research, 11, 4898-4904.
68. Sato, S., Kajiyama, Y., Sugano, M., Iwanuma, Y., Sonoue, H., Matsumoto, T., et al. (2005). Monoclonal antibody to Her-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein. International Journal of Radiation Oncology, Biology, Physics, 61, 203-211.
69. Pegram, M. D., Lopez, A., Konecny, G., & Slamon, D. J. (2000). Trastuzumab and chemotherapeutics: Drug interactions and synergies. Seminars in Oncology, 27, S21-S25.
70. Safran, H., Dipetrillo, T., Akerman, P., Ng, T., Evans, D., Steinhoff, M., et al. (2007). Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma. International Journal of Radiation Oncology, Biology, Physics, 67, 405-409.
71. Kato, H., Yoshikawa, M., Miyazaki, T., Nakajima, M., Fukai, Y., Masuda, N., et al. (2002). Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1) in esophageal squamous cell carcinoma. Anticancer Research, 22, 3977-3984.
72. Kleespies, A., Guba, M., Jauch, K. W., & Bruns, C. J. (2004). Vascular endothelial growth factor in esophageal cancer. Journal of Surgical Oncology, 87, 95-104.
73. Ogata, Y., Fujita, H., Yamana, H., Sueyoshi, S., & Shirouzu, K. (2003). Expression of vascular endothelial growth factor as a prognostic factor in node-positive squamous cell carcinoma in the thoracic esophagus: Long term follow-up study. World Journal of Surgery, 27, 584-589.
74. Couverland, A., Paraf, F., Gratio, V., Scoazec, J. Y., Hénin, D., Degott, C., et al. (2000). Angiogenesis in the neoplastic sequence of Barrett's esophagus. Correlation with VEGF expression. Journal of Pathology, 192, 14-18.
75. Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., Krummen, L., et al. (1997). Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Research, 57, 4593-4599.
76. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., et al. (2004). Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. New England Journal of Medicine, 350, 2335-2342.
77. Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., et al. (2006). Paclitaxel-carboplatin alone or with bevacizumab for non small-cell lung cancer. New England Journal of Medicine, 355, 2542-2550.
78. Shah, M. A., Ramanathan, R. K., Ilson, D. H., Levnor, A., D'Adamo, D., O'Reilly, E., et al. (2006). Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinomas. Journal of Clinical Oncology, 24, 5201-5206.
79. Enzinger, P. C., Fidias, P., Meyerhardt, J., Stuart, K., Fuchs, C., Huberman, M., et al. (2006). Phase II study of Bevacizumab and Docetaxel in metastatic esophageal and gastric cancer. Proceedings of the American Society of Clinical Oncology GI Cancers Symposium, Abstr 68.
80. Sunitinib FDA approval (2007). Avaible at www.fda.gov/cder/Offices/OODP/ whatsnew/sunitinib.htm.
81. Ratain, M. J., Eisen, T., Stadler, W. M., Flaherty, K. T., Kaye, S. B., Rosner, G. L., et al. (2006). Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology, 24, 2505-2512.
82. Kane, R. C., Farrell, A. T., Saber, H., Tang, S., Williams, G., Jee, J. M., et al. (2006). Sorafenib for the treatment of advanced renal cell carcinoma. Clinical Cancer Research, 12, 7271-7278.
83. Kerins, D. M., Murray, R., & Fitzgerald, G. A. (1991). Prostacyclin and prostaglandin E1: Molecular mechanisms and therapeutic utility. Progress in Hemostasis and Thrombosis, 10, 307-337.
84. Mestre, J. R., Subbaramaiah, K., Sacks, P. G., Schantz, S. P., Tanabe, T., Inoue, H., et al. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Research, 57, 2890-2895.
85. Subbaramaiah, K., Altorki, N., Chung, W., Mestre, J. R., Sampat, A., & Dannenberg, A. J. (1999). Inhibition of cyclooxygenase-2 gene expression by p53. Journal of Biological Chemistry, 274, 10911-10915.
86. Kelley, D. J., Mestre, J. R., Subbaramaiah, K., Sacks, P. G., Schantz, S. P., Tanabe, T., et al. (1997). Benzo[a]pyrene up-regulates cyclooxygenase-2 gene expression in oral epithelial cells. Carcinogenesis, 18, 795-799.
87. Zimmermann, K. C., Sarbia, M., Weber, A. A., Borchard, F., Gabbert, H. E., & Schrör, K. (1999). Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Research, 59, 198-204.
88. Yu, H. P., Xu, S. Q., Liu, L., Shi, L. Y., Cai, X. K., Lu, W. H., et al. (2003). Cyclooxygenase-2 expression in squamous dysplasia and squamous cell carcinoma of the esophagus. Cancer Letters, 198, 193-201.
89. Yu, H. P., Shi, L. Y., Lu, W. H., Su, Y. H., Li, Y. Y., & Xu, S. Q. (2004). Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Journal of Gastroenterology and Hepatology, 19, 638-642.
90. Shamma, A., Yamamoto, H., Doki, Y., Okami, J., Kondo, M., Fujiwara, Y., et al. (2000). Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clinical Cancer Research, 6, 1229-1238.
91. Zhi, H., Wang, L., Zhang, J., Zhou, C., Ding, F., Luo, A., et al. (2006). Significance of COX-2 expression in human esophageal squamous cell carcinoma. Carcinogenesis, 27, 1214-1221.
92. Bhandari, P., Bateman, A. C., Mehta, R. L., Stacey, B. S., Johnson, P., Cree, I. A., et al. (2006). Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically respectable adenocarcinomas of the esophagus. BMC Cancer, 6, 134.
93. Alici, S., Ugras, S., Bayram, I., & Izmirli, M. (2006). Prognostic factors and COX-2 expression in advanced stage esophageal squamous cell carcinoma. Advances in Therapy, 23, 672-679.
94. Liu, J. F., Jamieson, G., Wu, T. C., Zhang, S. W., Wang, Q. Z., & Drew, P. (2006). Cyclooxygenase-2 expression in squamous cell carcinoma of the esophagus. Diseases of the Esophagus, 19, 350-354.
95. Xi, H., Baldus, S. E., Warnecke-Eberz, U., Brabender, J., Neiss, S., Metzger, R., et al. (2005). High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. Clinical Cancer Research, 11, 8341-8347.
96. Takatori, H., Natsugoe, S., Okumura, H., Matsumoto, M., Ishigami, S., Owaki, T., et al. (2005). Predictive value of COX-2 for the effect of chemoradiotherapy on esophageal squamous cell carcinoma. Oncology Reports, 13, 697-701.
97. France, M., Drew, P. A., Dodd, T., & Watson, D. I. (2004). Cyclo-oxygenase-2 expression in esophageal adenocarcinomas as a determinant of clinical outcome following esophagectomy. Diseases of the Esophagus, 17, 136-140.
98. Buskens, C. J., Van Rees, B. P., Sivula, A., Reitsma, J. B., Haglund, C., Bosma, P. J., et al. (2002). Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinomas of the esophagus. Gastroenterology, 122, 1800-1807.
99. Pai, R., Soreghan, B., Szabo, I. L., Pavelka, M., Baatar, D., & Tarnawski, A. S. (2002). Prostaglandin E2 transactivates RGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nature Medicine, 8, 289-293.
100. Liu, X. H., Yao, S., Kirschenbaum, A., & Levine, A. C. (1998). NS398, a selective cycloogenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Research, 58, 4245-4249.
101. Souza, R. F., Shewmake, K., Beer, D. G., Cryer, B., & Spechler, S. J. (2000). Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinomas cells. Cancer Research, 60, 5767-5772.
102. Gallo, O., Franchi, A., Magnelli, L., Sardi, I., Vannacci, A., Boddi, V., et al. (2001). Cyclooxygenase -2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia, 3, 53-61.
103. Kase, S., Osaki, M., Honjo, S., Adachi, H., Tsujitani, S., Kaibara, N., et al. (2003). Expression of cyclo-oxygenase-2 is correlated with high intratumoral microvessel density and low apoptotic index in human esophageal squamous cell carcinomas. Virchows Archiv, 442, 129-135.
104. Tsujii, M., Kawano, S., & DuBois, R. N. (1997). Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proceedings of the National Academy of Sciences of the United States of America, 94, 3336-3340.
105. Corley, D. A., Kerlikowske, K., Verma, R., & Buffler, P. (2003). Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysis. Gastroenterology, 124, 47-56.
106. Kase, S., Osaki, M., Honjo, S., Takeda, A., Adachi, K., Araki, K., et al. (2004). A selective cyclooxygenase-2 inhibitor, NS398, inhibits cell growth and induces cell cycle arrest in the G2/m phase in human esophageal squamous cell carcinoma cells. Journal of Experimental & Clinical Cancer Research, 23, 301-307.
107. Li, M., Wu, X., & Xu, X. C. (2001). Induction of apoptosis by cyclo-oxygenase-2 inhibitor NS398 through a cytochrome C-dependent pathway in esophageal cancer cells. International Journal of Cancer, 93, 218-223.
108. Moore, R. J., Zweifel, B. S., Heuvelman, D. M., Leahy, K. M., Edwards, D. A., Woerner, B. M., et al. (2000). Enhanced antitumor activity by co-administration of celecoxib and the chemotherapeutic agents, cyclophosphamide and 5-FU. Proceedings of the American Association for Cancer Research, 41, 409.
109. Milas, L., Kishi, K., Hunter, N., Mason, K., Masferrer, J. L., & Tofilon, P. J. (1999). Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. Journal of the National Cancer Institute, 91, 1501-1504.
110. Dawson, S. J., Michael, M., Biagi, J., Foo, K. F., Jefford, M., Ngan, S. Y., et al. (2007). A phase I/II trial of celecixib with chemotherapy and radiotherapy in the treatment of patients with locally advanced eosophageal cancer. Investigational New Drugs, 25, 123-129.
111. Govindan, R., Mcleod, H., Mantravadi, P., Fineberg, N., Helft, P., Kesler, K., et al. (2004). Cisplatin, fluouracil, celecoxib, and RT in respectable esophageal cancer: Preliminary results. Oncology, 14, 18-21.
112. Enzinnger, P., Mamon, H., & Choi, N. C., Bueno, R., Kulke, M., Fidias, P., et al. (2004). Phase II cisplatin, irinotecan, celecoxib and concurrent radiation therapy followed by surgery for locally ]advanced esophageal cancer. Presented at: ASCO Gastrointestinal Cancer Symposium.
113. Yamashita, K., Mori, M., Kataoka, A., Inoue, H., & Sugimachi, K. (2001). The clinical significance of MMP-1 expression in oesophageal carcinoma. British Journal of Cancer, 84, 276-282.
114. Li, J. R., Qi, F. Y., & Li, L. (2005). Correlation between expression of matrix metalloproteinase-2 and angiogenesis in esophageal carcinoma. Zhonghua Zhong Liu Za Zhi, 27, 96-98.
115. Yamashita, K., Mori, M., Shiraishi, T., Shibuta, K., & Sugimachi, K. (2000). Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. Clinical Cancer Research, 6, 1169-1174.
116. Gu, Z. D., Chen, K. N., Li, M., Gu, J., & Li, J. Y. (2005). Clinical significance of matrix metalloproteinase-9 expression in esophageal sqamous cell carcinoma. World Journal of Gastroenterology, 11, 871-874.
117. Gu, Z. D., Li, J. Y., Li, M., Gu, J., Shi, X. T., Ke, Y., et al. (2005). Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma. American Journal of Gastroenterology, 100, 1835-1843.
118. Tierney, G. M., Griffin, N. R., Stuart, R. C., Kasem, H., Lynch, K. P., Lury, J. T., et al. (1999). A pilot study of the safety and effects of the matrix metalloproteinase inhibitor marimastat in gastric cancer. European Journal of Cancer, 35, 563-568.
119. Bramhall, S. R., Hallissey, M. T., Whiting, J., Scholefield, J., Tierney, G., Stuart, R. C., et al. (2002). Marimastat as maintenance therapy for patients with advanced gastric cancer: A randomised trial. British Journal of Cancer, 86, 1864-1870.
120. Heath, E. I., Burtness, B. A., Kleinberg, L., Salem, R. R., Yang, S. C., Heitmiller, R. F., et al. (2006). Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloproteinase (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Investigational New Drugs, 24, 135-140.
121. Pavlaki, M., & Zucker, S. (2003). Matrix metalloproteinase inhibitors (MMPIs): The beginning of phase I or termination of phase III clinical trials. Cancer and Metastasis Reviews, 22, 177-203.
122. Schwartz, G. K. (2005). Development of cell cycle active drugs for the treatment of gastrointestinal cancers: A new approach to cancer therapy. Journal of Clinical Oncology, 23, 4499-4508.
123. Kawakubo, H., Ozawa, S., Ando, N., Kitagawa, Y., Mukai, M., Ueda, M., et al. (2005). Alternations of p53, cyclin D1 and Prb expression in the carcinogenesis of esophageal squamous cell carcinoma. Oncology Reports, 14, 1453-1459.
124. Koppert, L. B., Wijnhoven, B. P., van Dekken, H., Tilanus, H. W., & Dinjens, W. N. (2005). The molecular biology of esophageal adenocarcinoma. Journal of Surgical Oncology, 92, 169-190.
125. Bani-Hani, K., Martin, I. G., Hardie, L. J., Mapstone, N., Briggs, J. A., Forman, D., et al. (2000). Prospective study of cyclin D1 overexpression in Barrett's esophagus: Association with increased risk of adenocarcinoma. Journal of National Cancer Institute, 92, 1316-1321.
126. Milas, L., Akimoto, T., Hunter, N. R., Mason, K. A., Buchmiller, L., Yamakawa, M., et al. (2002). Relationship between cyclin D1 expression and poor radioresponse of murine carcinomas. International Journal of Radiation Oncology, Biology, Physics, 52, 514-521.
127. Swanton, C. (2004). Cell-cycle targeted therapies. Lancet Oncology, 5, 27-36.
128. Senderowicz, A. M. (2003). Small-molecule cyclin-dependent kinase modulators. Oncogene, 22, 6609-6620.
129. Sato, S., Kajiyama, Y., Sugano, M., Iwanuma, Y., & Tsurumaru, M. (2004). Flavopiridol as a radiosensitizer for esophageal cancer cell lines. Diseases of the Esophagus, 17, 338-344.
130. Motwani, M., Rizzo, C., Sirotnak, F., She, Y., & Schwartz, G. K. (2003). Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Molecular Cancer Therapeutics, 2, 549-555.
131. Jung, C., Motwani, M., Kortmansky, J., Sirotnak, F. M., She, Y., Gonen, M., et al. (2003). The cyclin-dependent kinase inhibitor flavopiridol potentiates γ-irradiation-induced apoptosis in colon and gastric cancer cells. Clinical Cancer Research, 9, 6052-6061.
132. Raju, U., Ariga, H., Koto, M., Lu, X., Pickett, J., Valdecanas, D., et al. (2006). Improvement of esophageal adenocarcinoma cell and xenograft responses to radiation by targeting cyclin-dependent kinases. Radiotherapy and Oncology, 80, 185-191.
133. Schwartz, G. K., Ilson, D., Saltz, L., O'Reilly, E., Tong, W., Maslak, P., et al. (2001). Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. Journal of Clinical Oncology, 19, 1985-1992.
134. Schwartz, G. K., O'Reilly, E., Ilson, D., Saltz, L., Sharma, S., Tong, W., et al. (2002). Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumours. Journal of Clinical Oncology, 20, 2157-2170.
135. Rothkopf, D. E., Ilson, D. H., Yi, S., Winkelmann, J., Kelsen, D. P., & Schwartz, G. K. (2004). A phase II trial of sequential paclitaxel and flavopiridol in patients with metastatic paclitaxel-refractory esophageal cancer. Program and Abstracts of the American Society of Clinical Oncology 2004 Gastrointestinal Cancers Symposium, 67, Abstr 116.
136. Shah, M. A., Kortmansky, J., Gonen, M., Tse, A., Lefkowitz, R., Kelsen, D., et al. (2004). Phase I study of weekly irinotecan (CPT), cisplatin (CIS) and flavopiridol (F). Proceedings of the American Society of Clinical Oncology, 23, 319.
137. Yu, X., Guo, Z. S., Marcu, M. G., Neckers, L., Nguyen, D. M., Chen, G. A., et al. (2004). Modulation of P53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. Journal of the National Cancer Institute, 94, 504-513.
138. Gartel, A. L., & Tyner, A. L. (2002). The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Molecular Cancer Therapeutics, 1, 639-649.
139. Nguyen, D. M., Schrump, W. D., Tsai, W. S., Chen, A., Stewart, J. H., IV, Steiner, F., et al. (2003). Enhancement of depsipeptide- mediated apoptosis of lung or esophageal cancer cells by flavopiridol: Activation of the mitochondria-dependent death-signalling pathway. Journal of Thoracic and Cardiovascular Surgery, 125, 1132-1142.
140. Baldwin, A. S. (1996). The Nk-kappa B and I kappa B proteins: New discoveries and insights. Annual Review of Immunology, 14, 649-683.
141. Abdel-Latif, M. M., O'Riordan, J., Windle, H. J., Carton, E., Ravi, N., Kelleher, D., et al. (2004). NF-kappaB activation in esophageal adenocarcinoma: Relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Annals of Surgery, 239, 491-500.
142. Izzo, J. G., Malhotra, U., Wu, T. T., Ensor, J., Luthra, R., Lee, J. H., et al. (2006). Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. Journal of Clinical Oncology, 24, 748-754.
143. Li, J., Minnich, D. J., Camp, E. R., Brank, A., Mackay, S. L., & Hochwald, S. N. (2006). Enhanced sensitivity to chemotherapy in esophageal cancer though inhibition of NF-kappaB. Journal of Surgical Research, 132, 112-120.
144. Shah, M. A., Holen, K., Singh, D., Kemeny, M., Levner, A., Cox, L., et al. (2005). A multicenter, two-stage, phase II study of PS-341 in patients with unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Program and Abstracts of the American Society of Clinical Oncology 2005 Gastrointestinal Cancers Symposium, 103, Abstr 41.